Switch theme
Sign up to access all valuation multiples
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
2010
233
Last FY Revenue n/a
LTM EBITDA -$115M
$92.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Seres Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$115M.
In the most recent fiscal year, Seres Therapeutics achieved revenue of n/a and an EBITDA of -$120M.
Seres Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Seres Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$3.5M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$115M | XXX | -$120M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$109M | XXX | -$121M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$5.0M | XXX | $0.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Seres Therapeutics's stock price is $7.
Seres Therapeutics has current market cap of $61.7M, and EV of $92.3M.
See Seres Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $92.3M | $61.7M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Seres Therapeutics has market cap of $61.7M and EV of $92.3M.
Seres Therapeutics's trades at 0.7x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Seres Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Seres Therapeutics has a P/E ratio of -12.4x.
See valuation multiples for Seres Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61.7M | XXX | $61.7M | XXX | XXX | XXX |
| EV (current) | $92.3M | XXX | $92.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.4x | XXX | 453.3x | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSeres Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Seres Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Seres Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Seres Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Seres Therapeutics acquired XXX companies to date.
Last acquisition by Seres Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Seres Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Seres Therapeutics founded? | Seres Therapeutics was founded in 2010. |
| Where is Seres Therapeutics headquartered? | Seres Therapeutics is headquartered in United States of America. |
| How many employees does Seres Therapeutics have? | As of today, Seres Therapeutics has 233 employees. |
| Who is the CEO of Seres Therapeutics? | Seres Therapeutics's CEO is Mr. Eric D. Shaff. |
| Is Seres Therapeutics publicy listed? | Yes, Seres Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Seres Therapeutics? | Seres Therapeutics trades under MCRB ticker. |
| When did Seres Therapeutics go public? | Seres Therapeutics went public in 2015. |
| Who are competitors of Seres Therapeutics? | Similar companies to Seres Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Seres Therapeutics? | Seres Therapeutics's current market cap is $61.7M |
| Is Seres Therapeutics profitable? | Yes, Seres Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Seres Therapeutics? | Seres Therapeutics's last 12 months EBITDA is -$115M. |
| What is the current EV/EBITDA multiple of Seres Therapeutics? | Current EBITDA multiple of Seres Therapeutics is -0.8x. |
| What is the current FCF of Seres Therapeutics? | Seres Therapeutics's last 12 months FCF is -$29.4M. |
| What is the current EV/FCF multiple of Seres Therapeutics? | Current FCF multiple of Seres Therapeutics is -3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
